CVS Health Corporation – Consensus ‘buy’ rating and 19.1% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

CVS Health Corporation which can be found using ticker (CVS) now have 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $93.21 and $69.67 suggesting an average Analsyt target price of $81.68. Given that the stocks previous close was at $68.60 and the analysts are correct then there would likely be a percentage uptick in value of 19.1%. There is a 50 day moving average of $75.31 and the 200 day MA is $72.74. The market capitalization for the company is 87.46B. The current share price for the company is: $69.39 USD

The potential market cap would be $104,141,650,000 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 10.72, revenue per share of $277.53 and a 3.68% return on assets.

CVS Health Corporation, together with its subsidiaries, is a diversified health solutions company. The Company’s segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Its Health Care Benefits offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and diagnostic testing.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search